Quantcast

Latest Amgen Stories

2014-10-01 16:27:17

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel(®) (etanercept) and ABP 501 (adalimumab biosimilar) at the 23(rd) Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to...

2014-09-25 12:29:32

DUBLIN, Sept. 25, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 Kalorama Information's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry,...

2014-09-24 16:26:34

THOUSAND OAKS, Calif., Sept. 24, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will host a summary webcast of Kyprolis(®) (carfilzomib) for Injection data presented at the European Society for Medical Oncology (ESMO) 2014 Congress on Monday, Sept. 29, 2014, at 1 p.m. PT. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc., along with clinical investigators, will participate in the call. In addition, they...

2014-09-23 12:30:59

DUBLIN, Sept. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are...

2014-09-22 08:29:14

FDA Submission Reinforces Commitment to Addressing Significant Unmet Needs for Patients With Acute Lymphoblastic Leukemia, an Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is...

2014-09-15 16:29:02

Data Presented at the American Society of Bone and Mineral Research 2014 Annual Meeting THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia(®) (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic T-scores (>-2.5) at the lumbar spine and...

2014-09-15 16:28:40

Romosozumab Currently in Phase 3 Clinical Development, Pivotal Data Expected in 2016 THOUSAND OAKS, Calif. and BRUSSELS, Sept. 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels:UCB) today announced results from several exploratory analyses of the Phase 2 study evaluating romosozumab in postmenopausal women with low bone mineral density (BMD). Romosozumab is an investigational bone-forming agent that is designed to work by inhibiting the protein sclerostin, thereby...

2014-09-14 20:20:15

Analysis From SHIFT Study Shows Ivabradine Reduced Cardiovascular Death or Hospitalization for Worsening Heart Failure Independent of Baseline Blood Pressure With Similar Safety Profile Across Groups THOUSAND OAKS, Calif., Sept. 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18(th)...

2014-09-10 08:32:41

Data Include Eight Year Analyses of Bone Mineral Density Results for Prolia® (Denosumab) and Further Evidence for Significant Bone-Building With Romosozumab THOUSAND OAKS, Calif., Sept. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from multiple Prolia(®) (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting being held in Houston, Sept. 12-15, 2014. The data that will be...

2014-09-05 16:23:16

THOUSAND OAKS, Calif., Sept. 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014, at the Grand Hyatt New York in New York City, beginning at 9:10 a.m. ET. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related